Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q2

2160.TEDINET S100ROIG
Period2023-01-01 → 2023-06-30
Filed2023-08-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥14.1bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥9.9bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥8.2bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.2bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income¥5.5bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥5.1bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income¥1.0bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥526m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax¥5.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.2bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥790m2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥443m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.7bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.7bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥676m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥325m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥4.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥198m2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥126m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥45.1bnat 2023-06-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥35.3bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥20.3bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥24.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥21.8bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥23.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.0bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥14.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.5bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥872m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥389m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.5bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥3.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥267m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥34.932023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥34.992023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥14.252022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.862022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥34.812023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥34.882023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥14.182022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.832022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio51.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.5%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-06-30¥1.3bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-06-30¥512m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-06-30¥5.0bn
—segment totalrevenue2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥23m
—segment totalsegment profit2023-01-01 → 2023-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-06-30¥526m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-06-30¥479m
—segment totalrevenue2022-01-01 → 2022-06-30¥8.2bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥8.2bn
—segment totalsegment profit2022-01-01 → 2022-06-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 670
ItemContextValueUnit
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-38000JPY
Other fin cf IFRSPrior1YTDDuration-11022000JPY
Other fin cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-267292000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration3942881000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration1489531000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration797472000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration114694000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration3027443000JPY
Cash and cash equivalents IFRSPrior2YearInstant14352133000JPY
Cash and cash equivalents IFRSPrior1YearInstant11049310000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant14466828000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant14076753000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember6989504000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1165313000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember8154817000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration8154817000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember6989504000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1165313000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember8154817000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue IFRSPrior1YTDDuration8154817000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember479123000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember525544000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember1004668000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSPrior1YTDDuration1004668000JPY
Finance income IFRSPrior1YTDDuration175775000JPY
Finance costs IFRSPrior1YTDDuration390055000JPY
Profit loss before tax IFRSPrior1YTDDuration790388000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember12768126000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1328418000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember14096545000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration14096545000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember23197000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember23197000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-23197000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember12768126000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1351615000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember14119742000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-23197000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass